Mai Sato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mai Sato has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Koichi Kamei
National Center for Child Health and Development
2 shared publicationsMasao Ogura
National Center for Child Health and Development
2 shared publications- Shuichi Ito
National Center for Child Health and Development
2 shared publications - Fumio Mizuno
Tohoku Institute of Technology (Japan)
1 shared publication - Ippei Miyata
Department of Pediatrics, Kawasaki Medical School, Okayama, Japan
1 shared publication Isao Miyairi
National Center for Child Health and Development
1 shared publication
Latest Publications
- 1 January 2019
- Published by Japan Society of Mechanical Engineers in The Proceedings of JSME annual Conference on Robotics and Mechatronics (Robomec)
- Vol. 2019, 1P2-B05
Development of a fundamental measuring system to analyze motion and contact force during toothbrushing
Periodontal disease develops around gingiva and periodontal tissues and is morbidity which affects functions of gingiva and periodontal tissues. It is major disease as well as dental caries and considered to be one of the causes of cardio vascular disease such as arteriosclerosis or hypertension. Therefore, prevention of periodontal disease is deeply related to prevention chronic cardiovascular disease. The best way of prevention of periodontal disease is to learn proper toothbrushing to scrape plaque because periodontal disease is caused by bacteria in plaque which accumulates between teeth and gingiva. To learn or assess toothbrushing, some assistive devices combining toothbrush with sensor system were suggested. Most of them are equipped with only motion sensor to analyze the motion of toothbrush. We assumed that contact forces are important not only movements of toothbrush. In this work, we developed a fundamental measuring system to analyze motion and contact force during toothbrushing.
- 1 January 2019
- Published by Japan Society of Mechanical Engineers in The Proceedings of JSME annual Conference on Robotics and Mechatronics (Robomec)
- Vol. 2019, 1P2-B05
Development of a fundamental measuring system to analyze motion and contact force during toothbrushing
Periodontal disease develops around gingiva and periodontal tissues and is morbidity which affects functions of gingiva and periodontal tissues. It is major disease as well as dental caries and considered to be one of the causes of cardio vascular disease such as arteriosclerosis or hypertension. Therefore, prevention of periodontal disease is deeply related to prevention chronic cardiovascular disease. The best way of prevention of periodontal disease is to learn proper toothbrushing to scrape plaque because periodontal disease is caused by bacteria in plaque which accumulates between teeth and gingiva. To learn or assess toothbrushing, some assistive devices combining toothbrush with sensor system were suggested. Most of them are equipped with only motion sensor to analyze the motion of toothbrush. We assumed that contact forces are important not only movements of toothbrush. In this work, we developed a fundamental measuring system to analyze motion and contact force during toothbrushing.
- 7 March 2014
- Published by Springer Nature in Pediatric Nephrology
- Vol. 29 (8) , 1373-1379
Impact of rituximab on height and weight in children with refractory steroid-dependent nephrotic syndrome
Children with steroid-dependent nephrotic syndrome (SDNS) often suffer from serious adverse events, including growth retardation and obesity. Rituximab (RTX) is a promising therapeutic option to overcome steroid dependency. We have examined the impact of RTX on growth and obesity in children with SDNS. Thirteen pediatric patients with SDNS who were refractory despite treatment with multiple immunosuppressive agents received RTX infusions. Mean follow-up was 2.3 years from the first administration of RTX. Improvement in the height and obesity indexes from prior to the initial RTX infusion through to the last visit was assessed. After RTX, the number of relapses [2.8 (before RTX) vs. 0.8/year (after RTX); p = 0.0008] and the prednisolone dose (287.9 vs. 70.7 mg/kg/year, respectively; p = 0.0002) were significantly decreased. Marked improvement in the height standard deviation score (SDS) was achieved by ten of the 13 patients (77 %) [n = 13; −1.6 (before RTX) vs. −0.8 SDS (after RTX); p = 0.03]. Notably, the height SDS of seven of the eight patients whose height was less than average at the first RTX improved from −2.6 to −1.4 SDS with RTX therapy. At the same time, the obesity index of 12 of the 13 patients (92 %) significantly improved (n = 13; 16.9 vs. 3.1 %; p = 0.004). Therapy with RTX may contribute to an improvement in the growth and obesity indexes in some patients suffering from severe side effects of steroids.
- 7 March 2014
- Published by Springer Nature in Pediatric Nephrology
- Vol. 29 (8) , 1373-1379
Impact of rituximab on height and weight in children with refractory steroid-dependent nephrotic syndrome
Children with steroid-dependent nephrotic syndrome (SDNS) often suffer from serious adverse events, including growth retardation and obesity. Rituximab (RTX) is a promising therapeutic option to overcome steroid dependency. We have examined the impact of RTX on growth and obesity in children with SDNS. Thirteen pediatric patients with SDNS who were refractory despite treatment with multiple immunosuppressive agents received RTX infusions. Mean follow-up was 2.3 years from the first administration of RTX. Improvement in the height and obesity indexes from prior to the initial RTX infusion through to the last visit was assessed. After RTX, the number of relapses [2.8 (before RTX) vs. 0.8/year (after RTX); p = 0.0008] and the prednisolone dose (287.9 vs. 70.7 mg/kg/year, respectively; p = 0.0002) were significantly decreased. Marked improvement in the height standard deviation score (SDS) was achieved by ten of the 13 patients (77 %) [n = 13; −1.6 (before RTX) vs. −0.8 SDS (after RTX); p = 0.03]. Notably, the height SDS of seven of the eight patients whose height was less than average at the first RTX improved from −2.6 to −1.4 SDS with RTX therapy. At the same time, the obesity index of 12 of the 13 patients (92 %) significantly improved (n = 13; 16.9 vs. 3.1 %; p = 0.004). Therapy with RTX may contribute to an improvement in the growth and obesity indexes in some patients suffering from severe side effects of steroids.
- 31 October 2013
- Published by Springer Nature
- p. 181-194
Conclusion
- 5 September 2012
- Published by Springer Nature in Pediatric Nephrology
- Vol. 28 (1) , 145-149
Atypical Pneumocystis jiroveci pneumonia with multiple nodular granulomas after rituximab for refractory nephrotic syndrome
Rituximab, an anti-CD20 antibody that targets B cells, is a promising agent against steroid-dependent and steroid-resistant nephrotic syndrome in children. We report a 3-year-old boy who presented with atypical Pneumocystis jiroveci pneumonia (PCP) following administration of rituximab for refractory nephrotic syndrome. He had received cyclosporine and daily prednisolone for over 1 year. Following rituximab therapy, a hazy shadow was observed on his chest X-ray. Chest-computed tomography revealed multiple nodular lesions in bilateral lungs, although his clinical symptoms were subtle. PCR analysis demonstrated the presence of Pneumocystis DNA in his bronchoalveolar lavage. Lung wedge resection of the nodular lesion exhibited granulomas containing a few cysts of P. jiroveci that primarily consisted of T cells and histiocytes and lacked B cells. A deficiency of B cells following rituximab treatment suggests a dramatic effect on the immune response and, therefore, could result in granulomatous PCP. Nodular granulomatous lesions of PCP comprise an emerging concept previously reported in adults with hematological disease, bone marrow transplant, or treatment with rituximab. We report the first pediatric case of nodular PCP. Granulomatous PCP can be life-threatening. Moreover, bronchoalveolar lavage often fails to demonstrate the presence of P. jiroveci DNA. Wedge biopsy is warranted for definitive diagnosis. Our patient fully recovered with sulfamethoxazole/trimethoprim treatment because of early detection. The indication of rituximab for refractory nephrotic syndrome has increased recently. Therefore, recognition of the risk of atypical PCP is important. Our findings suggest that PCP prophylaxis should be considered following rituximab therapy.
- 5 September 2012
- Published by Springer Nature in Pediatric Nephrology
- Vol. 28 (1) , 145-149
Atypical Pneumocystis jiroveci pneumonia with multiple nodular granulomas after rituximab for refractory nephrotic syndrome
Rituximab, an anti-CD20 antibody that targets B cells, is a promising agent against steroid-dependent and steroid-resistant nephrotic syndrome in children. We report a 3-year-old boy who presented with atypical Pneumocystis jiroveci pneumonia (PCP) following administration of rituximab for refractory nephrotic syndrome. He had received cyclosporine and daily prednisolone for over 1 year. Following rituximab therapy, a hazy shadow was observed on his chest X-ray. Chest-computed tomography revealed multiple nodular lesions in bilateral lungs, although his clinical symptoms were subtle. PCR analysis demonstrated the presence of Pneumocystis DNA in his bronchoalveolar lavage. Lung wedge resection of the nodular lesion exhibited granulomas containing a few cysts of P. jiroveci that primarily consisted of T cells and histiocytes and lacked B cells. A deficiency of B cells following rituximab treatment suggests a dramatic effect on the immune response and, therefore, could result in granulomatous PCP. Nodular granulomatous lesions of PCP comprise an emerging concept previously reported in adults with hematological disease, bone marrow transplant, or treatment with rituximab. We report the first pediatric case of nodular PCP. Granulomatous PCP can be life-threatening. Moreover, bronchoalveolar lavage often fails to demonstrate the presence of P. jiroveci DNA. Wedge biopsy is warranted for definitive diagnosis. Our patient fully recovered with sulfamethoxazole/trimethoprim treatment because of early detection. The indication of rituximab for refractory nephrotic syndrome has increased recently. Therefore, recognition of the risk of atypical PCP is important. Our findings suggest that PCP prophylaxis should be considered following rituximab therapy.